711 related articles for article (PubMed ID: 31275326)
1. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.
Yan D; Adeshakin AO; Xu M; Afolabi LO; Zhang G; Chen YH; Wan X
Front Immunol; 2019; 10():1399. PubMed ID: 31275326
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer.
Wang Y; Jia A; Bi Y; Wang Y; Liu G
Cells; 2020 Apr; 9(4):. PubMed ID: 32325683
[TBL] [Abstract][Full Text] [Related]
3. β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME.
Mohammadpour H; MacDonald CR; McCarthy PL; Abrams SI; Repasky EA
Cell Rep; 2021 Oct; 37(4):109883. PubMed ID: 34706232
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming of myeloid-derived suppressor cells: An innovative approach confronting challenges.
Li X; Li Y; Yu Q; Qian P; Huang H; Lin Y
J Leukoc Biol; 2021 Aug; 110(2):257-270. PubMed ID: 34075637
[TBL] [Abstract][Full Text] [Related]
5. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
6. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Reprogramming of Myeloid-derived Suppressor Cells in the Tumor Microenvironment.
Liu L; Huo S; Liu J; Li Q; Wang J
Discov Med; 2021; 31(164):141-146. PubMed ID: 35188888
[TBL] [Abstract][Full Text] [Related]
8. Connections between Metabolism and Epigenetic Modification in MDSCs.
Dai H; Xu H; Wang S; Ma J
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027968
[TBL] [Abstract][Full Text] [Related]
9. Mutualistic Effects of the Myeloid-Derived Suppressor Cells and Cancer Stem Cells in the Tumor Microenvironment.
Tanriover G; Aytac G
Crit Rev Oncog; 2019; 24(1):61-67. PubMed ID: 31679221
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
11. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
Qu P; Wang LZ; Lin PC
Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
[TBL] [Abstract][Full Text] [Related]
12. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
Chen Z; Yuan R; Hu S; Yuan W; Sun Z
Front Immunol; 2022; 13():817942. PubMed ID: 35154134
[TBL] [Abstract][Full Text] [Related]
13. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects.
Uehara T; Eikawa S; Nishida M; Kunisada Y; Yoshida A; Fujiwara T; Kunisada T; Ozaki T; Udono H
Int Immunol; 2019 Mar; 31(4):187-198. PubMed ID: 30508092
[TBL] [Abstract][Full Text] [Related]
14. The immunobiology of myeloid-derived suppressor cells in cancer.
Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
[TBL] [Abstract][Full Text] [Related]
15. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.
Adeshakin AO; Adeshakin FO; Yan D; Wan X
Front Immunol; 2022; 13():781660. PubMed ID: 35140716
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.
Li Q; Xiang M
Acta Pharmacol Sin; 2022 Jun; 43(6):1337-1348. PubMed ID: 34561553
[TBL] [Abstract][Full Text] [Related]
17. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
Huo S; Liu L; Li Q; Wang J
Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
20. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Li BH; Garstka MA; Li ZF
Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]